Endonovo Therapeutics AI Stock Analysis
Want to see ENDV full AI Analyst Report?
Endonovo Therapeutics (ENDV) AI Stock Analysis
Endonovo Therapeutics
(Other OTC:ENDV)
Endonovo Therapeutics' stock score is heavily impacted by its poor financial performance and lack of positive technical indicators. The company's financial instability, highlighted by negative equity and inconsistent cash flow, presents significant risks. Valuation metrics further reflect these challenges, and the absence of earnings call data adds to uncertainty. The overall score reflects these concerns, suggesting a need for caution and strategic restructuring to improve long-term prospects.
Endonovo Therapeutics (ENDV) vs. SPDR S&P 500 ETF (SPY)
Not enough price history over this period.
- Market Cap
- $31.88K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 280.11
- Revenue Growth
- ―
- EPS Growth
- 48.00%
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Endonovo Therapeutics Business Overview & Revenue Model
Company Description
Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is S...
How the Company Makes Money
Endonovo Therapeutics primarily generates revenue through the sale and lease of its SofPulse devices to hospitals, clinics, and other healthcare facilities. The company's revenue model includes direct sales, leasing arrangements, and service agreemen...
Endonovo Therapeutics Peers Comparison
Overall Rating
NUWE47Neutral
BJDX44Neutral
DRMA40Underperform
SCNI39Underperform
PRFX37Underperform
ENDV35Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $2.65M | -0.00 | -408.34% | ― | 10.28% | 95.85% | |
| 44Neutral | $2.92M | -0.11 | -113.80% | ― | ― | 95.46% | |
| 40Underperform | $3.06M | -0.19 | -189.68% | ― | ― | 83.79% | |
| 39Underperform | $541.29K | 0.00 | -23.86% | ― | 143.06% | 94.98% | |
| 37Underperform | $2.38M | -0.07 | -72.87% | ― | ― | ― | |
| 35Underperform | $180.76K | -0.08 | 7.76% | ― | ― | 48.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ENDV | Endonovo Therapeutics, Inc. | ― | ― | ― | |
| NUWE | Nuwellis, Inc. | 4.90 | -767.48 | -99.37% | |
| SCNI | Scinai Immunotherapeutics Ltd. Sponsored Adr | 0.40 | -9.22 | -95.84% | |
| PRFX | Painreform Ltd. | 0.78 | -3.64 | -82.30% | |
| DRMA | Dermata Therapeutics, Inc. | 0.62 | -2.22 | -78.13% | |
| BJDX | Bluejay Diagnostics, Inc. | 2.61 | -20.27 | -88.59% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 02, 2025
